U.S.-listed shares of Canadian cannabis companies rallied in premarket trade Friday, after a better-than-expected earnings report from market leader Canopy Growth Corp.
bolstered hopes for the beaten-down sector. Canopy reported a narrower-than-expected fiscal third-quarter loss and revenue that rose above forecasts, amid strength in business-to-consumer sales. The report comes a day after Aurora Cannabis
reported a more than C$1 billion loss for its latest quarter. MKM analyst Bill Kirk said Canopy’s report was a beacon of hope for the sector and should boost sentiment. “We had expected only small improvements from the prior quarter, but Canopy is showing a meaningful progression,” Kirk wrote in a note to clients. Still, the path to profitability remains unclear and Kirk is waiting for the earnings call for details on Cannabis 2.0, the second phase of Canadian legalization that allows derivatives, including edibles and beverages. “We doubt early 2.0 sales will be a significant contributor given the lack of activity observed at production facilities two weeks before 2.0 legalization,” he wrote. “We continue to rate WEED shares Neutral.” Canopy’s U.S.-listed shares rose 18% premarket. Aurora was up 7%, Cronos
rose 6%, Tilray
was up 7%, Aphria
was up 8% and Organigram
was up 6%. The ETFMG Alternative Harvest ETF
has fallen 54% in the last 12 months, while the S&P 500
has gained 23%.